GH Research PLC (GHRS)
Market Cap | 447.96M |
Revenue (ttm) | n/a |
Net Income (ttm) | -34.97M |
Shares Out | 52.03M |
EPS (ttm) | -0.67 |
PE Ratio | n/a |
Forward PE | n/a |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 41,589 |
Open | 8.56 |
Previous Close | 8.62 |
Day's Range | 8.41 - 8.89 |
52-Week Range | 5.05 - 14.99 |
Beta | 0.74 |
Analysts | Strong Buy |
Price Target | 36.67 (+325.9%) |
Earnings Date | Nov 19, 2024 |
About GHRS
GH Research PLC, together with its subsidiary GH Research Ireland Limited, engages in developing various therapies to treat psychiatric and neurological disorders. It is involved in the development of 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD). The company’s lead program is GH001, an inhalable mebufotenin product candidate, currently under Phase 2b clinical trial for the treatment of patients with TRD, as well as Phase 2a clinical trials for the treatment of Bip... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 3 analysts, the average rating for GHRS stock is "Strong Buy." The 12-month stock price forecast is $36.67, which is an increase of 325.90% from the latest price.
News
GH Research Reports Second Quarter 2024 Financial Results and Provides Business Updates
DUBLIN, Sept. 03, 2024 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders,...
GH Research Announces Appointment of Dr. Velichka “Villy” Valcheva to Chief Executive Officer
DUBLIN, Ireland, Sept. 03, 2024 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological d...
GH Research Reports First Quarter 2024 Financial Results and Provides Business Updates
DUBLIN, Ireland, May 03, 2024 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological dis...
GH Research Reports Full Year 2023 Financial Results and Provides Business Updates
DUBLIN, Ireland, Feb. 29, 2024 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological di...
GH Research Announces Grant of European Patent Covering all Mebufotenin (5-MeO-DMT) and Mebufotenin Salt Products For Use in the Treatment of Major Depressive Disorder and Treatment-Resistant Depression
DUBLIN, Ireland, Jan. 18, 2024 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological di...
GH Research Reports Third Quarter Financial Results and Provides Business Updates
DUBLIN, Ireland, Nov. 09, 2023 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological di...
GH Research Provides Updates and Guidance on its Clinical Development Program for GH001 in Treatment-Resistant Depression
DUBLIN, Ireland, Sept. 29, 2023 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological d...
GH Research Reports Second Quarter 2023 Financial Results and Provides Business Updates
DUBLIN, Ireland, Aug. 23, 2023 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological di...
GH Research: But Toad Venom Is A Controlled Substance
GH Research PLC is developing mebufotenin, developed from toad venom, as an antidepressant. They have some early positive data. However, toad venom is a controlled substance and will face approval dif...
GH Research Reports First Quarter 2023 Financial Results and Provides Business Highlights
DUBLIN, Ireland, May 11, 2023 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological dis...
GH Research Reports Full Year 2022 Financial Results and Provides Business Updates
DUBLIN, Ireland, March 02, 2023 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological d...
Psychedelic Sunday: Competitive Strategies
Stephen Tobin on investing in psychedelic stocks while they're still pre-revenue. Will first-movers get the advantage?
GH Research Provides Business Updates and Highlights Key Upcoming Milestones
DUBLIN, Ireland, Jan. 09, 2023 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological di...
GH Research Reports Third Quarter 2022 Financial Results and Provides Business Updates
DUBLIN, Ireland, Nov. 10, 2022 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological di...
GH Research Reports Second Quarter 2022 Financial Results and Provides Business Updates
DUBLIN, Ireland, Aug. 23, 2022 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological di...
GH Research Reports First Quarter 2022 Financial Results and Provides Business Updates
DUBLIN, Ireland, May 18, 2022 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological dis...
GH Research Reports Full Year 2021 Financial Results and Provides Business Updates
DUBLIN, Ireland., March 28, 2022 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological ...
Revive Therapeutics, GH Research Among Top Psychedelic Movers Of Today
Revive Therapeutics (OTC:RVVTF) shares closed up 14.94% at $0.25 ATAI Life Sciences (NASDAQ:ATAI) shares closed up 3.53% at $5.58
GH Research Announces Positive Trial Results For Treatment-Resistant Depression
Clinical-stage biopharmaceutical company GH Research PLC (NASDAQ: GHRS) announced positive results from recent clinical trials of its leading 5-MeO-DMT formula, a therapy candidate for patients suffer...
GH Research Posts Data From Treatment-Resistant Depression Trial
GH Research PLC (NASDAQ: GHRS) has reported the outcome of the Phase 2 part of a Phase 1/2 trial of GH001, an inhalable 5-MeO-DMT product candidate for treatment-resistant depression (TRD). The trial ...
GH Research Reports Third Quarter 2021 Financial Results and Provides Business Updates
DUBLIN, Ireland, Dec. 06, 2021 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological di...
GH Research PLC Provides Business Updates and Reports Second Quarter 2021 Financial Results
DUBLIN, Ireland, Sept. 23, 2021 (GLOBE NEWSWIRE) -- GH Research PLC (NASDAQ: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological d...
GH Research: A Recent IPO Stock That Could Possibly Be A Trailblazer In A Hot Industry
The WHO predicts that depression will be the biggest problem in the world during the next decade and beyond. GH Research had a rather successful IPO on the 24th of June.
7 Companies Go Public Today. What Investors Need to Know.
Acurx Pharmaceuticals, Alpha Teknova, Elevation Oncology, GH Research, Graphite Bio, and MissFresh are listed on the Nasdaq. Mister Car Wash is trading the New York Stock Exchange.
GH Research Seeks $125 Million IPO
GH Research has filed proposed terms for a $125 million U.S. IPO. The firm is developing treatments for treatment resistant depression and other neurological conditions.